Gut Liver.
2021 Jan;15(1):135-141. 10.5009/gnl19302.
A Prospective Multicenter Study of Partially Covered Metal Stents in Patients Receiving Neoadjuvant Chemotherapy for Resectable and Borderline Resectable Pancreatic Cancer: BTS-NAC Study
- Affiliations
-
- 1Department of Gastroenterology, Graduate School of Medicine, The University of Tokyo, Japan.
- 2Department of Gastroenterology, Graduate School of Medicine, Juntendo University, Tokyo, Japan.
- 3Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University, Saitama, Japan.
- 4Department of Gastroenterology and Hepatology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
- 5Department of Gastroenterology and Hepatology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.
- 6Department of Gastroenterology, Teine-Keijinkai Hospital, Sapporo, Japan.
- 7Division of Gastroenterology, Tohoku University Graduate School of Medicine, Sendai, Japan.
- 8Second Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
- KMID: 2513685
- DOI: http://doi.org/10.5009/gnl19302
Abstract
- Background/Aims
The aim of this study was to evaluate the safety and efficacy of partially covered self-expandable metallic stents (PCSEMS) in patients undergoing neoadjuvant chemo (radio) therapy (NAC) for pancreatic cancer (PC).
Methods
This was a prospective multicenter study to evaluate the safety and efficacy of PCSEMS in patients receiving NAC for resectable and borderline resectable PC. The primary endpoint was the rate of recurrent biliary obstruction (RBO).
Results
Twenty-six patients with PC (three with resectable PC and 23 with borderline resectable PC) who underwent NAC at seven Japanese centers were included in the analysis. Both the technical and functional success rates of PCSEMS placement were 100%. Early stent-related complications were observed in three patients (11.5%): mild pancreatitis (n=2) and mild liver abscess (n=1). The median time to surgery or palliation was 4.0 months. Surgical resection was eventually performed in 73.1% of patients, and stent removal during surgery was successful in all patients. RBO was observed in nine patients (34.6%): seven with stent occlusion, one with kinking and one with migration. The RBO rates in resected cases and nonresected cases were 36.8% and 28.6%, respectively.
Conclusions
Biliary drainage by PCSEMS was safe and feasible in patients undergoing NAC for resectable and borderline resectable PC.
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- Neoadjuvant Therapy for Resectable or Borderline Resectable Pancreatic Cancer
- Neoadjuvant and Adjuvant Treatments for Resectable and Borderline Resectable Pancreatic Ductal Adenocarcinoma: The Current Status of Pancreatic Ductal Adenocarcinoma Treatment in Japan
- Systematic Review of Research Progress on Borderline Resectable Pancreatic Cancer: A Bibliometric and Visualized Analysis
- Survival benefit of neoadjuvant FOLFIRINOX for patients with borderline resectable pancreatic cancer
- Updates of Chemotherapy for Pancreatic Cancer
